Alkem Laboratories Q2 Revenue Rises 13.8% to ₹4,520 Crore
Key highlights
- Alkem Laboratories reported Q2 FY27 revenue from operations of ₹4,520 crore, up 13.8% year-on-year.
- EBITDA was ₹1,025 crore and the EBITDA margin was 22.5% in Q2 FY27.
- Alkem's chronic portfolio grew 22.4%, exceeding the industry's 16% growth by 640 basis points.
- Management expects close to 11% India business growth for FY27 and targets over 50 bps of annual EBITDA-margin improvement from FY28.
powered by IRIS

Alkem Laboratories Ltd reported Q2 FY27 revenue from operations of ₹4,520 crore, up 13.8% year-on-year, supported by India formulations and international operations, while its chronic portfolio grew 22.4%, outperforming the Indian Pharmaceutical Market growth of 16% in the segment.
Know Alkem Laboratories inside out
Results, valuation, peers and who's buying, in one view.
What did Alkem report for Q2 FY27?
Alkem reported revenue from operations of ₹4,520 crore for Q2 FY27, representing year-on-year growth of 13.8%. EBITDA was ₹1,025 crore, up 11.3% year-on-year, and the EBITDA margin stood at 22.5%. The company said gross margin expanded by 220 basis points year-on-year to 67.2%.
Net profit declined 11.7% year-on-year, while profit before tax increased 7.7%. Research and development expense accounted for 4.3% of revenue. Alkem also reported net cash of more than ₹4,900 crore at the end of the quarter, providing a view of its balance-sheet position alongside the quarterly operating metrics.
How did Alkem's India formulations and chronic therapies perform?
Alkem's India formulations business grew 13.8% year-on-year, matching the 13.8% growth reported for the Indian Pharmaceutical Market, according to IQVIA data cited by the company. Acute therapies grew 12.1%, broadly in line with the market's 12.3% growth in that segment.
The chronic portfolio was the stronger component of the India business. Alkem's chronic segment grew 22.4%, compared with 16% growth for the industry, an outperformance of 640 basis points. Management identified chronic therapies as a strategic priority because the company's chronic business accounts for roughly 24% to 25% of its India mix, compared with an industry split described as 65% chronic and 35% acute.
Chief Executive Officer Dr Amrut Naik said the company is focusing on anti-diabetic, cardiovascular, neuropsychiatry and dermatology therapies. These categories are central to Alkem's stated effort to expand its presence in chronic treatments, where its current business mix remains below the broader industry's chronic exposure.
Got a follow-up? Ask IRIS
What affected profitability and international operations?
Alkem's reported margin performance reflected a 22.5% EBITDA margin, but management did not raise its FY27 margin outlook. The company indicated that FY27 margin could remain near FY26's 20.4% level. The integration of Occlutech was cited as a factor, with the medtech business expected to create an approximately 80-basis-point drag on the consolidated margin.
Medtech sales were ₹133 crore during the quarter, including Occlutech. Management said it would take about 1.5 years for the acquired business to reach EBITDA break-even, compared with an earlier FY27 break-even target. Non-US markets delivered steady underlying performance led by Latin America, while reported growth also benefited from the Occlutech integration.
Biotech sales were ₹70 crore, down 35% year-on-year. Management attributed the decline to the lumpy nature of the CDMO business rather than a stated change in its longer-term plan. It retained its expectation of CDMO EBITDA break-even in about 1.5 to two years and outlined an ambition to roughly double revenue over four years.
The US business remained a constraint in the quarter. US constant-currency sales declined 3% because of price erosion, and management described FY27 US growth as likely to be in the single digits. The Daman facility's official action indicated status continued to delay US approvals; responses have been submitted, but the timing of an FDA re-audit was not specified.
What guidance and operating targets did management provide?
Alkem expects India business growth of close to 11% in FY27, according to Dr Naik. This projection is below the 13.8% India formulations growth measured by IQVIA in the quarter, reflecting management's comments that other businesses, including medtech, trade generics and biosimilars, can weigh on overall India growth.
Management maintained its broader FY27 margin stance rather than providing a higher target after the second-quarter result. For FY28, it stated a target for annual EBITDA-margin improvement of more than 50 basis points. The outlook depends in part on the progress of businesses currently in investment or integration phases, including Occlutech and CDMO.
Conclusion
Alkem's Q2 FY27 results showed revenue growth of 13.8% and a 22.5% EBITDA margin, with chronic therapies providing the clearest growth outperformance in the domestic portfolio. At the same time, the year-on-year decline in net profit, lower biotech sales and US price erosion show that the quarter contained uneven performance across business lines.
Investors will watch whether India business growth approaches management's close-to-11% FY27 expectation, how quickly Occlutech and CDMO move towards break-even, and when the Daman facility receives an FDA re-audit date. Management's stated FY28 target of more than 50 basis points of annual EBITDA-margin improvement is another disclosed operating milestone to track.


